Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sheri Skerget

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Plos Genetics|October 7, 2025
Immunophenotypic changes in the tumor and tumor microenvironment during progression to multiple myelomaIsabelle Bergiers, Murat Cem Köse, Sheri Skerget, et al.
Blood|April 24, 2024
Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 studyDiana Cortes-Selva, Tatiana Perova, Sheri Skerget, et al.
Blood|September 22, 2025
Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 studyAjai Chari, Niels W C J van de Donk, Bhagirathbhai Dholaria, et al.
Blood Advances|December 5, 2023
Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementationKristine A Frerichs, Christie P M Verkleij, Maria Victoria Mateos, et al.
Blood|February 8, 2022
Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myelomaGeorgina S F Anderson, Jose Ballester-Beltran, George Giotopoulos, et al.
Nature Medicine|January 15, 2026
Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myelomaHolly Lee, Sungwoo Ahn, Gerone A Gonzales, et al.
The Lancet. Haematology|March 16, 2025
Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 studyAjai Chari, Cyrille Touzeau, Carolina Schinke, et al.
Nature Genetics|August 19, 2024
Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypesSheri Skerget, Daniel Penaherrera, Ajai Chari, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Plos Genetics|October 7, 2025
Immunophenotypic changes in the tumor and tumor microenvironment during progression to multiple myelomaIsabelle Bergiers, Murat Cem Köse, Sheri Skerget, et al.
Blood|April 24, 2024
Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 studyDiana Cortes-Selva, Tatiana Perova, Sheri Skerget, et al.
Blood|September 22, 2025
Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 studyAjai Chari, Niels W C J van de Donk, Bhagirathbhai Dholaria, et al.
Blood Advances|December 5, 2023
Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementationKristine A Frerichs, Christie P M Verkleij, Maria Victoria Mateos, et al.
Blood|February 8, 2022
Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myelomaGeorgina S F Anderson, Jose Ballester-Beltran, George Giotopoulos, et al.
Nature Medicine|January 15, 2026
Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myelomaHolly Lee, Sungwoo Ahn, Gerone A Gonzales, et al.
The Lancet. Haematology|March 16, 2025
Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 studyAjai Chari, Cyrille Touzeau, Carolina Schinke, et al.
Nature Genetics|August 19, 2024
Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypesSheri Skerget, Daniel Penaherrera, Ajai Chari, et al.
Pageof 2